Long-term outcomes of autologous tranplantation in multiple myeloma: Significant survival benefit of novel drugs in post-transplantation relapse.

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	KREJČÍ Marta ŠČUDLA Vlastimil TOTHOVA Elen SCHUTZOVÁ Miroslava KOZA Vladimír ADAM Zdeněk KŘIVANOVÁ Andrea POUR Luděk BÜCHLER Tomáš SANDECKÁ Viera KRÁLOVÁ Dana ZAHRADOVÁ Lenka VORLÍČEK Jiří MAYER Jiří HÁJEK Roman
Year of publication	2009
Type	Article in Periodical
Magazine / Source	Clinical Lymphoma & Myeloma
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	bortezomib; complete response; thalidomide
Description	Autologous stem cell transplantation (autoSCT) has an important role in the treatment of patients with symptomatic multiple myeloma (MM). Treatment options for myeloma have expanded in the past decade, and it seems that patients who are treated with novel drugs such as thalidomide and bortezomib for relapse after autoSCT have longer overall survival (OS).
Related projects:	University Research Centre - Czech Myeloma Group From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies